Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024)
Cellectis' (CLLS) quarterly Non-Current Deferred Tax Liability came in at $118000.0 in Q3 2024, down 25.32% quarter-over-quarter from $158000.0 in Q4 2023.
Cellectis (CLLS) Non-Current Deferred Tax Liability (2023 - 2024) Analysis & Trends
Cellectis' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $118000.0 for Q3 2024.
- On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $118000.0 in Q3 2024; TTM through Sep 2024 was $118000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $158000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability retreated to $118000.0 in Q3 2024 per CLLS's latest filing, from $158000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $158000.0 in Q4 2023 and bottomed at $118000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 118,000.00 |
| Sep 30, 2024 | 118,000.00 |
| Dec 31, 2023 | 158,000.00 |
| Dec 31, 2023 | 158,000.00 |